FTC Chairwoman Lina Khan testifies during the House Appropriations Subcommittee on Financial Services and General Government hearing titled “Fiscal Year 2025 Request for the Federal Trade Commission,” in Rayburn Building on Wednesday, May 15, 2024. Tom Williams | Cq-roll Call, Inc. | Getty Images CVS Health, UnitedHealth Group and Cigna are demanding Federal Trade Commission…
Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Subcommittee at the Rayburn House Office Building on May 15, 2024 in Washington, DC. Kevin Dietsch | Getty Images News | Getty Images The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the…
Read More “FTC sues drug middlemen for allegedly inflating insulin prices” »
A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Earlier this…
Read More “Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock” »
Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug…
Read More “Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says” »
Dr. Scott Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is a CNBC contributor and is a member of the boards of Pfizer and several other startups in health and tech. He is also a partner at the venture capital firm New Enterprise Associates. Shani…
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its…
Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada. Ethan Miller | Getty Images Abbott Laboratories announced Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring…
Read More “FDA approves two new Abbott over-the-counter continuous glucose monitors” »
Exterior view of the Pfizer headquarters building in New York City on Jan. 29, 2023. Kena Betancur | Corbis News | Getty Images Pfizer on Wednesday said it has launched a new multiyear program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition…
Read More “Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts” »
Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, lower on Friday. Eli Lilly shares dropped…
